Published in J Am Coll Cardiol on March 12, 2013
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88
A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J (2006) 3.43
A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med (2008) 2.60
Factors associated with poorer prognosis for patients undergoing primary percutaneous coronary intervention during off-hours: biology or systems failure? JACC Cardiovasc Interv (2008) 2.22
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation (2004) 2.00
Hypercholesterolemia suppresses inwardly rectifying K+ channels in aortic endothelium in vitro and in vivo. Circ Res (2006) 1.85
Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries. Circ Cardiovasc Interv (2008) 1.84
Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol (2007) 1.77
Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation (2002) 1.45
Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv (2008) 1.44
Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol (2007) 1.40
The vulnerable artery: early and rapid deposition of lipid in coronary arteries is associated with subsequent development of thin-cap fibroatheromas. EuroIntervention (2016) 1.40
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA (2003) 1.36
Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proc Natl Acad Sci U S A (2005) 1.35
Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis (2006) 1.34
A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. Eur Heart J (2007) 1.30
The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol (2011) 1.30
Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature. Arterioscler Thromb Vasc Biol (2008) 1.21
Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther (2002) 1.17
Diagnosis of thin-cap fibroatheromas by a self-contained intravascular magnetic resonance imaging probe in ex vivo human aortas and in situ coronary arteries. J Am Coll Cardiol (2005) 1.11
Porcine models of coronary atherosclerosis and vulnerable plaque for imaging and interventional research. EuroIntervention (2009) 1.07
Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. Am J Cardiol (2003) 1.06
Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: a report from the National Heart, Lung, and Blood Institute-sponsored 1997-2006 dynamic registry. Circ Cardiovasc Qual Outcomes (2009) 1.04
Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis (2002) 1.03
Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents. Ann Pharmacother (2006) 1.02
Ethnic differences in the presentation, treatment strategy, and outcomes of percutaneous coronary intervention (a report from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol (2003) 1.00
Site specific gene delivery in the cardiovascular system. J Control Release (2005) 0.99
Percutaneous coronary intervention of moderate to severe calcified coronary lesions: insights from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv (2011) 0.97
Electron-beam computerized tomography correlates with coronary angiogram in chronic kidney disease patients. Am J Nephrol (2007) 0.95
Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis (2013) 0.94
Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail (2013) 0.94
Porcine models of accelerated coronary atherosclerosis: role of diabetes mellitus and hypercholesterolemia. J Diabetes Res (2013) 0.93
Preclinical evaluation of drug-eluting stents for peripheral applications: recommendations from an expert consensus group. Circulation (2004) 0.93
Completeness of revascularization for multivessel coronary artery disease and its effect on one-year outcome: a report from the NHLBI Dynamic Registry. J Interv Cardiol (2007) 0.91
One-year clinical outcomes of protected and unprotected left main coronary artery stenting. Eur Heart J (2003) 0.90
Patient satisfaction is comparable to early discharge versus overnight observation after elective percutaneous coronary intervention. J Invasive Cardiol (2009) 0.89
Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J (2003) 0.89
Comparison of invasive and noninvasive assessment of aortic stenosis severity in the elderly. Circ Cardiovasc Interv (2012) 0.89
Hypercholesterolemia suppresses Kir channels in porcine bone marrow progenitor cells in vivo. Biochem Biophys Res Commun (2007) 0.88
Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans. J Clin Invest (2012) 0.88
Atherosclerotic plaque development. Int J Biochem Cell Biol (2009) 0.87
Effect of gender on prognosis following percutaneous coronary intervention for stable angina pectoris and acute coronary syndromes. Am J Cardiol (2006) 0.86
Akt pathway is hypoactivated by synergistic actions of diabetes mellitus and hypercholesterolemia resulting in advanced coronary artery disease. Am J Physiol Heart Circ Physiol (2010) 0.86
Vascular responses to drug-eluting and bare metal stents in diabetic/hypercholesterolemic and nonatherosclerotic porcine coronary arteries. Circ Cardiovasc Interv (2011) 0.86
Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis. JACC Cardiovasc Interv (2011) 0.85
Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol. Cytometry A (2009) 0.84
Intracoronary delivery of mesenchymal stem cells at high flow rates after myocardial infarction improves distal coronary blood flow and decreases mortality in pigs. Catheter Cardiovasc Interv (2009) 0.84
Outcome of percutaneous coronary intervention in unstable angina pectoris versus stable angina pectoris in two different time periods. Am J Cardiol (2006) 0.84
Intracoronary delivery of bone-marrow-derived stem cells. Stem Cell Res Ther (2010) 0.84
Quantitative angiography in South Asians reveals differences in vessel size and coronary artery disease severity compared to Caucasians. Am J Cardiovasc Dis (2011) 0.84
Comparison of bare-metal and drug-eluting stents in patients with chronic kidney disease (from the NHLBI Dynamic Registry). Am J Cardiol (2011) 0.83
Prediction of coronary events by intravascular imaging. JACC Cardiovasc Imaging (2012) 0.83
Preclinical evaluation of the engineered stem cell chemokine stromal cell-derived factor 1α analog in a translational ovine myocardial infarction model. Circ Res (2013) 0.83
Subsequent development of fibroatheromas with inflamed fibrous caps can be predicted by intracoronary near infrared spectroscopy. Arterioscler Thromb Vasc Biol (2013) 0.81
Darapladib. Expert Opin Investig Drugs (2010) 0.80
Local drug delivery for treatment of coronary and peripheral artery disease. Cardiovasc Ther (2010) 0.79
Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). Am J Cardiol (2007) 0.79
Adenovirus-catheter compatibility increases gene expression after delivery to porcine myocardium. Hum Gene Ther (2003) 0.79
Recent developments with lipoprotein-associated phospholipase A2 inhibitors. Curr Atheroscler Rep (2010) 0.78
Drug-eluting stents are here--now what? Implications for clinical practice and health care costs. Cleve Clin J Med (2004) 0.78
Emerging therapies for acute coronary syndromes. Front Pharmacol (2011) 0.78
Early aneurysm formation after everolimus-eluting stent implantation. Circ Cardiovasc Interv (2014) 0.78
A novel ultrasound method for evaluation of collateral development in limb ischemia. Vasc Med (2002) 0.77
Intravascular magnetic resonance imaging. Top Magn Reson Imaging (2007) 0.77
Temporal variation in inhospital mortality with percutaneous coronary intervention: a report from the National Heart, Lung and Blood Institute Dynamic Registry. Am Heart J (2005) 0.77
Comparison of drug-eluting and bare metal stents for saphenous vein graft lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol (2010) 0.77
Minimally invasive resection of papillary fibroelastoma in a high-risk patient. J Cardiovasc Med (Hagerstown) (2007) 0.77
Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol (2002) 0.77
Usefulness of noncoronary vascular disease in predicting adverse events in the year following percutaneous coronary intervention. Am J Cardiol (2005) 0.77
Beta-cyclodextrin tetradecasulfate, a novel cyclic oligosaccharide, inhibits thrombus and neointimal formation after coronary vascular injury. Coron Artery Dis (2002) 0.77
Importance of the postdischarge interval in assessing major adverse clinical event rates following percutaneous coronary intervention. Am J Cardiol (2005) 0.77
Association of a unique cardiovascular risk profile with outcomes in Hispanic patients referred for percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol (2009) 0.76
New insights into the vulnerable plaque from imaging studies. Curr Atheroscler Rep (2014) 0.76
(18)F-fluoride imaging for atherosclerosis. J Am Coll Cardiol (2012) 0.75
Risk of death and myocardial infarction in patients with peripheral arterial disease undergoing percutaneous coronary intervention (from the National Heart, Lung and Blood Institute Dynamic Registry). Am J Cardiol (2011) 0.75
Relative contributions of intimal hyperplasia and vascular remodeling in early cardiac transplant-mediated coronary artery disease. Am J Cardiol (2003) 0.75
Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent. Am J Health Syst Pharm (2007) 0.75
Separate and combined effects of local and continuous intravenous administration of beta-cyclodextrin tetradecasulfate on intimal hyperplasia after angioplasty in porcine coronary arteries. J Cardiovasc Pharmacol Ther (2003) 0.75
Comparison of the efficacy of direct coronary stenting with sirolimus-eluting stents versus stenting with predilation by intravascular ultrasound imaging (from the DIRECT trial). Am J Cardiol (2006) 0.75
FilterWire distal embolic protection device for vein graft stenting: initial single-center experience. Clin Cardiol (2005) 0.75
Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction. Am J Cardiol (2003) 0.75
Reduced vascular complications after percutaneous coronary interventions with a nonmechanical suture device: results from the randomized RACE study. Catheter Cardiovasc Interv (2004) 0.75